Agilent Resolution ctDx FIRST assay
Liquid biopsy NGS assay using plasma cfDNA to detect KRAS G12C and EGFR variants in advanced NSCLC, guiding selection of targeted treatment options.
Casandra.ai provides a unified ordering experience so you can request this test directly from the performing lab, without changing your workflow.
Ordering is available where Casandra has an active integration with the performing lab. Labs that offer this test can connect with us to enable digital ordering.
About this test
Agilent Resolution ctDx FIRST is an FDA-approved, qualitative, targeted hybrid-capture NGS assay that analyzes circulating cell-free DNA from plasma to detect KRAS G12C and selected EGFR variants in patients with advanced non-small cell lung cancer. This single-site liquid biopsy test helps identify patients who may be eligible for KRAS G12C–directed and EGFR-targeted treatment strategies.
Where this test fits
| Indication | Biomarker | Biomarker details | Therapy (Select a therapy to open its FDA-approved testing pathway) |
|---|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | KRAS | G12C | KRAZATI |
Performing lab
Resolution Bioscience is dedicated to developing a highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients around the world. The company has developed and patented core technology for circulating cell-free DNA NGS analysis. The company is based in Kirkland, Washington.
Order this test
If your organization is connected to Casandra, you can place an electronic order forAgilent Resolution ctDx FIRST assay directly from your existing workflow.
Casandra connects providers, labs, and sponsored programs so that companion diagnostics can be ordered consistently and documented cleanly, regardless of which system you start from.